Rizik Suha, Hakim Fahed, Bentur Lea, Arad-Cohen Nira, Kassis Imad
Division of Pediatric Pulmonology.
Department of Pediatric Hemato-Oncology.
J Pediatr Hematol Oncol. 2018 Oct;40(7):532-535. doi: 10.1097/MPH.0000000000001283.
Immunocompromised children are at high risk of rapid deterioration and of developing life-threatening pulmonary infections. Etiologies in this setting are diverse, including those that are infectious and noninfectious, and many etiologies may coexist. Accurate diagnosis is required for the rational use of medications. Fiberoptic bronchoscopy (FOB) with bronchoalveolar lavage (BAL) can identify infectious causes in this population.
The aims of this study were to evaluate diagnostic rate, safety, and changes in treatment following FOB with BAL, when applied with advanced laboratory diagnostic techniques.
We reviewed the records of children who underwent FOB with BAL during the period spanning from 2006 to 2014 in the Hematology-Oncology Department. BAL samples were processed in microbiology, virology, cytology, and molecular laboratories.
Antimicrobials were initiated in 91 of 117 children. BAL yielded an infectious etiology in 55 episodes. Management was altered in 74 patients following a positive (40/55) or a negative (30/54) result (4 patients had missing data). No severe complications associated with the procedures occurred.
Most immunocompromised patients with pulmonary manifestations are treated empirically with multiple medications. Evaluation FOB/BAL is a useful diagnostic tool, and seems to have changed the course of therapy in more than half of patients, by initiation or cessation of treatment. FOB/BAL is a safe diagnostic tool for the evaluation of pulmonary manifestations in this setting.
免疫功能低下的儿童面临病情迅速恶化以及发生危及生命的肺部感染的高风险。这种情况下的病因多种多样,包括感染性和非感染性病因,且许多病因可能同时存在。合理用药需要准确诊断。纤维支气管镜检查(FOB)联合支气管肺泡灌洗(BAL)可识别该人群中的感染病因。
本研究的目的是评估在应用先进实验室诊断技术时,FOB联合BAL的诊断率、安全性以及治疗变化。
我们回顾了2006年至2014年期间在血液肿瘤科接受FOB联合BAL检查的儿童的记录。BAL样本在微生物学、病毒学、细胞学和分子实验室进行处理。
117名儿童中有91名开始使用抗菌药物。BAL在55例中发现了感染性病因。在获得阳性(40/55)或阴性(30/54)结果后,74例患者的治疗方案发生了改变(4例患者数据缺失)。未发生与操作相关的严重并发症。
大多数有肺部表现的免疫功能低下患者接受多种药物的经验性治疗。评估FOB/BAL是一种有用的诊断工具,通过开始或停止治疗,似乎改变了超过一半患者的治疗进程。FOB/BAL是评估这种情况下肺部表现的一种安全的诊断工具。